Gennex Laboratories Ltd (GENNEX) is currently trading at 8.70 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Gennex Laboratories Limited is an Indian vertically integrated pharmaceutical manufacturer producing bulk drugs, intermediates and biotech products, with GMP/CGMP-compliant facilities and an export-oriented footprint servicing multiple international markets from its manufacturing base in Andhra Pradesh, India. Q1 FY2027 standalone revenue was Rs. 3,467.79 lakhs, a year-on-year increase of approximately 35%, while consolidated revenue rose about 16.6% year-on-year to Rs. 3,984.17 lakhs, showing robust top-line recovery even as margins compressed compared with the prior-year quarter. Profit metrics show compression: standalone PBT fell to Rs. 420.53 lakhs from Rs. 484.95 lakhs year-on-year and consolidated PBT declined to Rs. 491.64 lakhs from Rs. 586.64 lakhs, reflecting higher raw material consumption and other cost pressures despite revenue growth across domestic and export markets. India remains the dominant market contributing roughly 73% of quarterly revenues, while exports to Vietnam, Colombia, Egypt and others provide diversification; the consolidated financials incorporate Deccan Remedies Limited after the 2023 acquisition, indicating group-level scale and intra-group trading.

Over the past 52 weeks, Gennex Laboratories Ltd has traded between a low of ₹7.05 and a high of ₹17.25. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Gennex Laboratories Ltd has a market capitalization of approximately 211.36. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Gennex Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 10.25 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 211.36 Cr, Gennex Laboratories Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Gennex Laboratories Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Gennex Laboratories Ltd is 10.25. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.